Endotronix develops the Cordella platform for proactive, remote heart failure management, focusing on monitoring pulmonary artery pressure and vital signs to guide therapy and improve patient outcomes. The company emphasizes home-based data collection and clinician-directed care, with FDA-approved devices and evidence-driven approaches for NYHA class III heart failure. Headquartered in the United States through its Edwards Lifesciences affiliation, Endotronix collaborates on advancing heart failure management and patient engagement.
No recent deals for this company.